Literature DB >> 21656104

Quantification of [18F]-FDG uptake in atherosclerotic plaque: impact of renal function.

Thorsten Derlin1, Christian R Habermann, Jasmin D Hahne, Ivayla Apostolova, Susanne Klutmann, Janos Mester, Ralph Buchert.   

Abstract

OBJECTIVE: Impaired renal function causes both increased and prolonged tracer availability in the blood-pool which might result in increased tracer accumulation in atherosclerotic lesions. Therefore, the aim of this study was to investigate a possible correlation between the intensity of tracer uptake in atherosclerotic lesions and renal function.
METHODS: Data from 50 [18F]-FDG scans were visually evaluated for tracer uptake in vessel wall alterations. Lesions were analyzed semiquantitatively by determining the blood-pool standardized uptake values (SUV(blood-pool)s), maximum SUVs (SUV(max)s), and the target-to-background ratio (TBR). These parameters were tested for correlation with estimated glomerular filtration rate (eGFR), and cardiovascular risk factors.
RESULTS: Both SUV(blood-pool)s (r(s) = -0.32, p = 0.03) and SUV(max)s for [18F]-FDG (r(s) = -0.50, p < 0.0001) showed a significant negative correlation with eGFR. TBRs for [18F]-FDG demonstrated a significant positive correlation with eGFRs (r(s) = 0.21, p = 0.02).
CONCLUSION: This study found that both intravascular tracer availability (SUV(blood-pool)) and intralesional tracer uptake (SUV(max)) are influenced by renal function. Calculation of TBR to account for that effect may result in overcorrection in case of [(18)F]-FDG. Renal insufficiency or subclinical changes in renal function have to be considered as a confounding factor in PET of atherosclerotic lesions.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21656104     DOI: 10.1007/s12149-011-0503-1

Source DB:  PubMed          Journal:  Ann Nucl Med        ISSN: 0914-7187            Impact factor:   2.668


  5 in total

1.  Comparison of FDG-PET/CT images between chronic renal failure patients on hemodialysis and controls.

Authors:  Akira Toriihara; Yoshio Kitazume; Hidenori Nishida; Kazunori Kubota; Masashi Nakadate; Ukihide Tateishi
Journal:  Am J Nucl Med Mol Imaging       Date:  2015-01-15

Review 2.  PET Imaging of Atherosclerotic Disease: Advancing Plaque Assessment from Anatomy to Pathophysiology.

Authors:  Nicholas R Evans; Jason M Tarkin; Mohammed M Chowdhury; Elizabeth A Warburton; James H F Rudd
Journal:  Curr Atheroscler Rep       Date:  2016-06       Impact factor: 5.113

3.  Monitoring plaque inflammation in atherosclerotic rabbits with an iron oxide (P904) and (18)F-FDG using a combined PET/MR scanner.

Authors:  A Millon; S D Dickson; A Klink; D Izquierdo-Garcia; J Bini; E Lancelot; S Ballet; P Robert; J Mateo de Castro; C Corot; Z A Fayad
Journal:  Atherosclerosis       Date:  2013-03-26       Impact factor: 5.162

4.  Internal tissue references for 18Fluorodeoxyglucose vascular inflammation imaging: Implications for cardiovascular risk stratification and clinical trials.

Authors:  Mark A Ahlman; Davis M Vigneault; Veit Sandfort; Roberto Maass-Moreno; Jenny Dave; Ahmed Sadek; Marissa B Mallek; Mariana A F Selwaness; Peter Herscovitch; Nehal N Mehta; David A Bluemke
Journal:  PLoS One       Date:  2017-11-13       Impact factor: 3.240

Review 5.  PET imaging of the neurovascular interface in cerebrovascular disease.

Authors:  Nicholas R Evans; Jason M Tarkin; John R Buscombe; Hugh S Markus; James H F Rudd; Elizabeth A Warburton
Journal:  Nat Rev Neurol       Date:  2017-10-06       Impact factor: 42.937

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.